Sibylle Loibl/gbg.de
Jun 27, 2025, 03:03
Sibylle Loibl: Final survival Results from the PENELOPE-B trial published in Annals of Oncology
Sibylle Loibl, Chief Executive Officer of GBG Forschungs GmbH, shared a post on LinkedIn:
“Final survival Results from the PENELOPE-B trial published in Annals of Oncology
Palbociclib fails to improve long-term survival in high-risk HR+/HER2− early breast cancer – but new hope for lobular breast cancer? The final analysis of the PENELOPE-B trial provides critical long-term data on the efficacy of CDK4/6 inhibition in early high-risk hormone receptor-positive (HR+)/HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy (NACT).
Study Design & Purpose
PENELOPE-B investigated whether the addition of 1 year of palbociclib to standard adjuvant endocrine therapy (ET) could improve outcomes for patients with high-risk HR+/HER2− breast cancer and residual invasive disease post-NACT.Key Findings (Median follow-up: 77.8 months)
No significant improvement in overall survival (OS) or invasive disease-free survival (iDFS) in the total study population. Results remained consistent across predefined subgroups.Exploratory Insight: Lobular Breast Cancer (LBC)
A glimmer of promise was observed in a post hoc analysis of patients with invasive lobular carcinoma (ILC):
iDFS significantly improved: HR 0.52 (95% CI 0.28–0.97, P = 0.035)
OS showed a strong trend: HR 0.45 (95% CI 0.19–1.07, P = 0.062)Conclusion
While the overall results did not support routine use of palbociclib in the adjuvant setting for HR+/HER2− early breast cancer, these findings highlight the need for further research into histological subtypes such as lobular breast cancer, where CDK4/6 inhibition might offer more benefit.”
Title: Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy
Authors: S. Loibl, M. Martin, H. Bonnefoi, M. Untch, S.-B. Kim, H.D. Bear, J.A. García-Sáenz, M. Melé Olivé, N. Mc Carthy, K. Gelmon, C.M. Kelly, S.-A. Im, T. Reimer, M. Martinez-Janez, Z. Zhang, M. Toi, L. Provencher, H.S. Rugo, M. Gnant, A. Makris, A. Antón Torres, N. Hirmas, J. Holtschmidt, V. Nekljudova, F. Marmé
Read the Full Article.
More posts featuring Sibylle Loibl.
A. Antón Torres
A. Makris
Annals of Oncology
Breast Cancer
C.M. Kelly
cancer
F. Marmé
H S Rugo
H. Bonnefoi
H.D. Bear
J. Holtschmidt
J.A. García-Sáenz
K. Gelmon
L. Provencher
M. Gnant
M. Martín
M. Martinez-Janez
M. Melé Olivé
M. Toi
M. Untch
N. Hirmas
N. Mc Carthy
OncoDaily
Oncology
S. Loibl
S.-A. Im
S.-B. Kim
Sibylle Loibl
T. Reimer
V. Nekljudova
Z. Zhang
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 19:30
Jun 26, 2025, 17:54
Jun 26, 2025, 17:47